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We are thrilled to announce the launch of MolecularTherapy— 
Nucleic Acids (MTNA), the second official journal of the Amer-
ican Society of Gene and Cell Therapy (ASGCT) and the first 
of what we hope will be a series of online-only, open-access 
sibling journals serving both members and nonmembers alike 
of the ASGCT. We launched the Oligonucleotide Therapeu-
tics section in Molecular Therapy (MT) in 2008 and have seen 
submissions grow strongly since then. In 2011, we published 
twice as many papers in this burgeoning field than just 3 years 
earlier. This impressive growth continues and the launch of 
MTNA thus provides an alternate venue for the ASGCT to 
publish more of the best of work in this field. At the same time, 
it ensures that we maintain a more generalist approach in MT 
so as to continue to provide balanced coverage of the diverse 
but overlapping fields that fall under the “molecular therapy” 
umbrella. Indeed, the concept of “targeted delivery” is front 
and center, whether we are discussing replacement cell ther-
apy, gene therapy, or therapeutics based on gene silencing. 
We also envisage less of an emphasis on animal model data 
in MTNA (although we certainly welcome such submissions), 
and a greater emphasis on early-stage development of novel 
oligonucleotide-based  strategies  (whether  vector-based  or 
delivered via nanoparticle formulations) and the mechanisms 
that underlie them. In addition, MT has recently seen strong 
growth of submissions in the field of genome engineering 
using natural and synthetic nucleases, and we have deliber-
ately decided to consider manuscripts in MTNA on this topic 
as well, owing to the potential impact of these new tools on 
the manipulation of gene expression and the development of 
gene-based therapies.
As noted in previous editorials in MT,1,2 these are chang-
ing times for science publishing. The growth and widespread 
global availability of the Internet has made possible the dis-
tribution of information on a scale that was not possible until 
the waning years of the last century. These changes have 
challenged long-standing models of publishing, including the 
publishing of primary scientific research, which long relied on 
limiting access to a small pool of academic subscribers at a 
relatively high cost and with poor overall circulation and dis-
tribution. The advent and growth of open-access publishing 
has changed all that by providing a complementary model 
for the dissemination of scientific information based on an 
author-pays model that allows availability to all. The benefits 
to authors are the widest possible distribution of the fruits of 
their scientific labor, including to those in developing regions 
of the world who might not otherwise gain access. For those 
investigators whose research is funded by the National Health 
Institutes (NIH), it also satisfies the requirement that the publi-
cation be openly accessible within 1 year of publication, which 
in the case of open access is immediate. The challenge of 
paying for this new model continues to develop, as research 
funders and publishers work to devise a cost-structure that 
maintains high standards of peer review and production, while 
also meeting the mandates for free access to the results of 
research efforts sponsored by particular research funders.
The advantages of open access also come with chal-
lenges. For it is not only the academic community who will 
benefit from greater access to the scientific literature, but 
of the entire Internet community worldwide, including many 
lay readers who have personal, commercial, or other inter-
ests in the development of treatments for any of a variety 
of diseases that currently lack effective therapies, but who 
may lack sufficient scientific background to put new findings 
into their proper context. The growth of medical tourism in 
the area of cell therapy provides a cautionary note, for it is 
important that we as authors, reviewers, editors, and pub-
lishers refrain from hyping new findings or from allowing 
their over-interpretation. The last thing we wish to do is to 
provide either false hope to those suffering from untreatable 
disorders, or ammunition for charlatans who wish to prey 
upon the latter. Despite this challenge,   scientists in coun-
tries and institutions with limited access to hard copy jour-
nals increasingly will have ready online access to research 
published anywhere in the world. We believe that this is how 
scientific findings should be disseminated, and in the end 
this will profit the global scientific and medical community.
The editors of MTNA welcome feedback from readers of 
all stripes on research articles, editorials, and commentaries 
published in the journal. We note that the views represented in 
editorials and commentaries represent those of their authors, 
and not necessarily those of either the editors or the ASGCT, 
unless otherwise noted. We are working this year with our 
NPG publishing partner on the development of a more interac-
tive functionality for reader feedback, which we hope to launch 
by year’s end. In the meantime, readers should feel free to 
submit rebuttals, commentaries, or other feedback directly by 
E-mail (mtna@molther.org), which we will consider for pos-
sible publication in the journal if deemed suitable.
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